Eli Lilly Acquires AtaiBeckley for Up to $3.8 Billion
Eli Lilly (LLY) is acquiring AtaiBeckley in a deal valued up to $3.8 billion, entering the psychedelic drug development space focused on mental health treatments like depression and social anxiety. The upfront payment of $2.8 billion includes potential milestone-based payments totaling an additional $1 billion.
Topics: depression treatment pharma psychedelic therapy psychiatry drugs